Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group

The aim of this study was to learn the toxicity and efficacy of adding 4 doses of rituximab to a standard platinum-based salvage regimen for relapsed CD20+ B-cell non-Hodgkin lymphoma. Patients were treated with rituximab 375 mg m2 days 1,8,15, 22 (cycle 1 only); cisplatin 100 mg m2 over 24 h on day...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2008-06, Vol.49 (6), p.1074-1080
Main Authors: Witzig, Thomas E., Geyer, Susan M., Kurtin, Paul J., Colgan, Joseph P., Inwards, David J., Micallef, Ivana N. M., LaPlant, Betsy R., Michalak, John C., Salim, Muhammad, Dalton, Robert J., Moore, Dennis F., Reeder, Craig B.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cisplatin - therapeutic use
Cytarabine - therapeutic use
Dexamethasone - therapeutic use
Female
Humans
Lymphoma, B-Cell, Marginal Zone - drug therapy
Lymphoma, Follicular - drug therapy
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Mantle-Cell - drug therapy
Lymphoma, Non-Hodgkin - drug therapy
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Non-Hodgkin lymphoma
Prognosis
Rituximab
salvage chemotherapy
Salvage Therapy
transplant
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to learn the toxicity and efficacy of adding 4 doses of rituximab to a standard platinum-based salvage regimen for relapsed CD20+ B-cell non-Hodgkin lymphoma. Patients were treated with rituximab 375 mg m2 days 1,8,15, 22 (cycle 1 only); cisplatin 100 mg m2 over 24 h on day 3, cytosine arabinoside 2 g m2 IV every 12 h × two doses on day 4, dexamethasone 40 mg PO IV days 3-6, and G-CSF days 5-14. The ORR was 82% (47 57) with 33% (19 57) complete remissions and 49% (28 57) partial remissions. The duration of response (DR) for the 47 responders was 10.5 months (95% CI: 5.3-16.8). The median time to progression (TTP) was 10.3 months (95% CI: 5.3-14.0), the median event-free survival (EFS) was 5.3 months (95% CI: 3.9-11.0), and the median overall survival was 30.5 months (95% CI: 17.8-60.6). We conclude that rituximab can be safely added to standard DHAP.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428190801993470